Trial Profile
Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM (Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs DTaP poliovirus vaccine (Primary)
- Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions
- Sponsors Sanofi Pasteur
- 14 May 2022 Results published in the Infectious Diseases and Therapy
- 04 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.
- 23 Sep 2011 New trial record